Detailed Abstract
[BP Poster Presentation 2 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP PP 2-7] A Prospective, Randomized Controlled Trial Of The Comparative Analysis Between Motilitone And Gasmotin For The Symptom Relief In Gallstone Patients With Functional Dyspepsia
Ji Su KIM1 , Ho Kyoung HWANG*2
1 Department Of Hepatobiliary And Pancreatic Surgery, The Catholic University Of Korea Incheon St. Mary’s Hospital, REPUBLIC OF KOREA
2 Department Of Hepatobiliary And Pancreatic Surgery, Yonsei University College Of Medicine, REPUBLIC OF KOREA
Background : Functional dyspepsia is common in patients with cholelithiasis and associated with decreased contractility of the gallbladder. Motilitone is a gastrointestinal motility stimulant that can increases gallbladder contractility. This study aimed to assess the efficacy of Motilitone on symptom relief in patients with cholelithiasis and functional dyspepsia.
Methods : This single center, prospective, randomized controlled trial included a total of 72 patients with cholelithiasis and functional dyspepsia based on predefined criteria. Patients were randomly assigned to take either Motilitone or Gasmotin for 6 months. The primary endpoint is changes in functional dyspepsia assessed on the Nepean dyspepsia index – Korean version (NDI-K symptom scale) after 3 and 6 months.
Results : The NDI-K total symptom score was not statistically different between the Motilitone and Gasmotin groups after 3 and 6 months (3, 6 months; adjusted p=0.41, adjusted p=0.43 by linear mixed effect model analysis). Dyspepsia sum score was not significantly different between two groups (3, 6 months; adjusted p=0.37, adjusted p=0.56). However, the degree of symptom improvement was better in total symptom score and dyspepsia sum score in Motilitone group after 3 and 6 months compared to before randomization (NDI-K total symptom score changes at 3, 6 months, adjusted p<0.0001, adjusted p<0.0001; dyspepsia sum score changes at 3, 6 months, adjusted p<0.0001, adjusted p<0.0001).
Conclusions : This study showed that Motilitone improved functional dyspepsia more effectively than Gasmotin in patients with cholelithiasis.
Methods : This single center, prospective, randomized controlled trial included a total of 72 patients with cholelithiasis and functional dyspepsia based on predefined criteria. Patients were randomly assigned to take either Motilitone or Gasmotin for 6 months. The primary endpoint is changes in functional dyspepsia assessed on the Nepean dyspepsia index – Korean version (NDI-K symptom scale) after 3 and 6 months.
Results : The NDI-K total symptom score was not statistically different between the Motilitone and Gasmotin groups after 3 and 6 months (3, 6 months; adjusted p=0.41, adjusted p=0.43 by linear mixed effect model analysis). Dyspepsia sum score was not significantly different between two groups (3, 6 months; adjusted p=0.37, adjusted p=0.56). However, the degree of symptom improvement was better in total symptom score and dyspepsia sum score in Motilitone group after 3 and 6 months compared to before randomization (NDI-K total symptom score changes at 3, 6 months, adjusted p<0.0001, adjusted p<0.0001; dyspepsia sum score changes at 3, 6 months, adjusted p<0.0001, adjusted p<0.0001).
Conclusions : This study showed that Motilitone improved functional dyspepsia more effectively than Gasmotin in patients with cholelithiasis.
SESSION
BP Poster Presentation 2
Poster Presentation 3/24/2023 2:50 PM - 3:50 PM